Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Missouri
Clinical trial register · United States · industry-sponsored

Clinical Trials in Missouri, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 127 Florida 117 Georgia 72 Colorado 64 Arizona 62
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Missouri

37 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 1
280
California, Florida, Missouri, Nebraska, Ohio, Rhode Island, Texas
2026-08-12
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Iowa, Massachusetts, Michigan, Missouri, New Jersey, New York
2026-07-06
Recruiting
Merck Sharp & Dohme LLC
Phase 1
120
Missouri, Texas
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Illinois, Missouri, Montana, Nebraska, Nevada
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 2
140
Arizona, California, Florida, Idaho, Maryland, Missouri, Nebraska, New York
2026-04-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Georgia, Kentucky, Missouri, New Jersey, New York, Tennessee
2026-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1
210
California, Florida, Kansas, Kentucky, Maryland, Missouri, New York, South Carolina
2026-01-13
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
Merck Sharp & Dohme LLC
Phase 1
126
Florida, Missouri, Texas
2025-10-08
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Arizona, California, Colorado, Florida, Illinois, Michigan, Missouri, Nebraska
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Arizona, California, Florida, Illinois, Maryland, Missouri, Montana, Nebraska
2025-09-26
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-05-26
Active, closed
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
California, Colorado, Florida, Illinois, Louisiana, Missouri, Nebraska, New York
2025-03-11
Active, closed
Merck Sharp & Dohme LLC
Phase 1
72
Florida, Georgia, Missouri, Tennessee
2024-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1
250
California, Florida, Missouri, Nebraska, Ohio, Oklahoma, Tennessee
2024-12-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington
2024-11-25
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2024-08-16
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
38
California, Illinois, Indiana, Massachusetts, Missouri, New York, Ohio, Utah
2024-07-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York
2024-05-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Arkansas, California, Florida, Indiana, Maryland, Mississippi, Missouri, Montana
2023-08-08
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
390
California, Colorado, Georgia, Indiana, Massachusetts, Missouri, New York, North Carolina
2023-06-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
California, Colorado, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-05-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
641
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Missouri, New Jersey
2023-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
514
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-02-17
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
48
California, Colorado, Illinois, Indiana, Missouri, New York, Ohio, Pennsylvania
2022-11-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
2,000
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Missouri, New Jersey
2021-09-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
California, Illinois, Iowa, Maryland, Massachusetts, Michigan, Missouri, New York
2021-08-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
District of Columbia, Florida, Kentucky, Maryland, Missouri, New Jersey, New York, Ohio
2020-05-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,033
California, Florida, Georgia, Idaho, Kansas, Kentucky, Missouri, Nevada
2020-02-27
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/missouri

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies with a site in Missouri that also match the filters currently applied.

How many clinical trials are recruiting in Missouri?

25 of the 37 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Missouri), 37 studies
PhaseStudiesRecruitingShare
Phase 312532.4%
Phase 29724.3%
Phase 1/27518.9%
Phase 16516.2%
Phase 2/3338.1%

Most active sponsors

Lead sponsors with the most studies (Missouri)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3725
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.